Phase I/II, multicenter, open-label study of intratumoral/intralesional administration of the retinoic acid-inducible gene I (RIG-I) activator MK-4621 in patients with advanced or recurrent tumors

被引：0
|
作者：
Middleton, M. R. [1 ]
Wermke, M. [2 ]
Calvo, E. [3 ]
Chartash, E. [4 ]
Zhou, H. [4 ]
Zhao, X. [4 ]
Niewel, M. [5 ]
Dobrenkov, K. [4 ]
Moreno, V. [6 ]
机构：
[1] Univ Oxford, Oncol, Oxford, England
[2] Univ Klinikum CG Carus, UCC Early Clin Trial Unit, Dresden, Germany
[3] Hosp Fdn Jimenez Diaz, Clin Res, START Madrid FJD, Madrid, Spain
[4] Merck & Co Inc, Med Oncol, Kenilworth, NJ USA
[5] Merck & Co Inc, Clin, Munich, Germany
[6] Hosp Fdn Jimenez Diaz, Med Oncol, START Madrid FJD, Madrid, Spain
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA16
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Multicenter, Open-Label, Phase I Study of DSP-7888 Dosing Emulsion in Patients with Advanced Malignancies
    Alexander Spira
    Aaron R. Hansen
    Wael A. Harb
    Kelly K. Curtis
    Erina Koga-Yamakawa
    Makoto Origuchi
    Zhonggai Li
    Bella Ertik
    Walid L. Shaib
    Targeted Oncology, 2021, 16 : 461 - 469
  • [22] Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037)
    Mitchell, Tara C.
    Hamid, Omid
    Smith, David C.
    Bauer, Todd M.
    Wasser, Jeffrey S.
    Olszanski, Anthony J.
    Luke, Jason J.
    Balmanoukian, Ani S.
    Schmidt, Emmett V.
    Zhao, Yufan
    Gong, Xiaohua
    Maleski, Janet
    Leopold, Lance
    Gajewski, Thomas F.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (32) : 3223 - +
  • [23] Nivolumab With or Without Ipilimumab in Patients With Recurrent or Metastatic Merkel Cell Carcinoma: A Nonrandomized, Open-Label, International, Multicenter Phase I/II Study
    Bhatia, Shailender
    Topalian, Suzanne L.
    Sharfman, William
    Meyer, Tim
    Steven, Neil
    Lao, Christopher D.
    Farinas-Madrid, Lorena
    Devriese, Lot A.
    Moore, Kathleen
    Ferris, Robert L.
    Honma, Yoshitaka
    Elias, Ileana
    Srirangam, Anjaiah
    Garnett-Benson, Charlie
    Lee, Michelle
    Nghiem, Paul
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (09)
  • [24] Efficacy and Safety of Avapritinib in Treating Unresectable or Metastatic Gastrointestinal Stromal Tumors: A Phase I/II, Open-Label, Multicenter Study
    Li, Jian
    Zhang, Xinhua
    Deng, Yanhong
    Wu, Xin
    Zheng, Zhichao
    Zhou, Yongjian
    Cai, Shirong
    Zhang, Yanqiao
    Zhang, Jun
    Tao, Kaixiong
    Cui, Yuehong
    Cao, Hui
    Shen, Kuntang
    Yu, Jiren
    Zhou, Ye
    Ren, Wenxiao
    Qu, Chenglin
    Zhao, Wanqi
    Hu, Jin
    Wang, Wei
    Yang, Jason
    Shen, Lin
    ONCOLOGIST, 2023, 28 (02): : 187 - +
  • [25] Phase I Open-Label Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Dilpacimab in Patients with Advanced Solid Tumors
    Gordon, Michael S.
    Nemunaitis, John
    Barve, Minal
    Wainberg, Zev A.
    Hamilton, Erika P.
    Ramanathan, Ramesh K.
    Sledge, George W., Jr.
    Yue, Huibin
    Morgan-Lappe, Susan E.
    Blaney, Martha
    Kasichayanula, Sreeneeranj
    Motwani, Monica
    Wang, Lan
    Naumovski, Louie
    Strickler, John H.
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (10) : 1988 - 1995
  • [26] A phase I open-label study investigating the disposition of [14C]-cabazitaxel in patients with advanced solid tumors
    Ridoux, Laurence
    Semiond, Dorothee R.
    Vincent, Carine
    Fontaine, Helene
    Mauriac, Christine
    Sanderink, Ger-Jan
    Oprea, Corina
    Kelly, Lindsay
    Clive, Sally
    ANTI-CANCER DRUGS, 2015, 26 (03) : 350 - 358
  • [27] A Phase I, open-label study investigating the disposition of [14C]-cabazitaxel in patients with advanced solid tumors
    Ridoux, Laurence
    Semiond, Dorothee
    Vincent, Carine
    Fontaine, Helene
    Mauriac, Christine
    Sanderink, Gerard
    Oprea, Corina
    Clive, Sally
    CANCER RESEARCH, 2012, 72
  • [28] A phase I open-label study of FGFR/VEGFR inhibitor FH-2001 in patients with advanced solid tumors
    Song, Zhengbo
    Hui, Ai-min
    Wu, Zhuli
    Liu, Huilong
    Cheng, Xiangdong
    CANCER RESEARCH, 2022, 82 (12)
  • [29] Durvalumab and tremelimumab in combination with metronomic oral vinorelbine for recurrent advanced cervical cancer: an open-label phase I/II study
    Frenel, Jean-Sebastien
    Mathiot, Laurent
    Cropet, Claire
    Borcoman, Edith
    Hervieu, Alice
    Coquan, Elodie
    de la Motte Rouge, Thibault
    Saada-Bouzid, Esma
    Sabatier, Renaud
    Lavaud, Pernelle
    Jimenez, Marta
    Legrand, Francois
    Le Saux, Olivia
    Charafe, Emmanuelle
    Goncalves, Anthony
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2025, 13 (01)
  • [30] A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and various degrees of hepatic function
    Slingerland, Marije
    Hess, Dagmar
    Clive, Sally
    Sharma, Sunil
    Sandstrom, Per
    Loman, Niklas
    Porro, Maria G.
    Mu, Song
    Waldron, Edward
    Valera, Sue-zette
    Gelderblom, Hans
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 74 (05) : 1089 - 1098
12345